Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

Is Johnson & Johnson Stock Outperforming the Nasdaq?

Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

5 Dividend Stocks Retirees Are Favoring for Steady Income in 2026

Retirees in 2026 are looking for something simple: predictable income without unnecessary risk. With inflation still pressuring household budgets and bond yields bouncing around, many...

Saving Advice

Anger, distress but $405m mesh implant payouts coming

Exasperation over lengthy wait for women to be compensated for pelvic mesh implant injuries has led to promises that money will start flowing soon.

AAP

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Stocks and ETFs to Help Shield Your Portfolio During Volatility

Resilient stocks and ETFs offering steady demand and dividend yields may help investors weather further market turbulence without abandoning equity exposure.

MarketBeat

Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs

Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is mixed. JNJ has many “Strong Buy” opinions, but some analysts consider JNJ overvalued. Today’s...

Barchart

What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock?

Although Johnson & Johnson has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

1 Dividend King to Buy and Hold Through Any Market

In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson Quietly Triggers a Trend Following Buy Signal

Johnson & Johnson is poised to advance in H2 2026 as growth, cash flow, and capital returns drive bullish analysts and institutional sentiment.

MarketBeat

Trump Speech, Earnings and Other Key Things to Watch this Week

Markets enter a holiday-shortened week with the Martin Luther King, Jr. Day closure Monday, followed by a convergence of events including President Trump's inauguration speech Wednesday at 8:30am

Barchart

'We don't want to fade away slowly' - Naomi Watts shares the important check many women miss in menopause

The star spoke exclusively to woman&home to share what she learnt about looking after her eyes in menopause

Woman & Home

2 Rock-Solid Dividend Stocks to Buy for Steady Passive Income

These two income stocks can weather every cycle.

Barchart

This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

MarketBeat

Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

MarketBeat

2 Dividend Kings Quietly Beating the Market This Year

These two are the calm outperformers that might have been overlooked.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Johnson & Johnson Ordered to Pay $65.5 Million to a Woman in Talcum Powder Cancer Case

A Minnesota jury ordered Johnson & Johnson to pay $65.5 million to a mother of three who linked her cancer to long-term use of the company's talcum powder.

Barchart

What to Expect From Johnson & Johnson’s Next Quarterly Earnings Report

Investor interest is building ahead of Johnson & Johnson’s Q4 earnings, backed by positive analyst sentiment.

The Independent UK

Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder

A Minnesota jury has awarded $65.5 million to a woman who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing mesothelioma

Barchart

3 Dividend Kings Delivering Generational Income & Market-Beating Returns

3 top-performing Dividend Kings of 2025 based on their Year-to-Date percent change.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Johnson & Johnson ordered to pay women over talcum powder cancer cases

The healthcare giant immediately announced its intention to appeal the liability verdict and compensatory damages

GOBankingRates

If You Bought 10 Shares of Johnson & Johnson 10 Years Ago, You’d Have This Much Today

If you bought 10 shares of Johnson & Johnson (JNJ) stock 10 years ago, this is how much it would be worth today.

International Business Times

Eli Lilly, Pfizer Among 19 Drugs Approved for China's Commercial Health Insurance

China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local drugmakers.

Benzinga

Applied Materials To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

MarketBeat

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

Barchart

3 Highest-Yielding Dividend Kings To Buy, Hold, and Forget

Discover three Dividend Kings built for buy-and-forget wealth. These stable giants may quietly deliver income and growth for decades.

Benzinga

Jim Cramer Recommends These 4 Dividend Stocks, Says Era Of 'Magical Investing' In AI Is 'Dead'

CNBC host Jim Cramer has become more cautious toward AI and data center stocks after seeing increasing insider selling and borrowing activity.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.